



PRODUCT: **NEXLIZET**

COMPANY: Esperion Therapeutics Inc.

THERAPEUTIC AREA & INDICATION:
Treatment of hypercholesterolemia

ABOUT THE PRODUCT

NEXLIZET is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Despite advances in lipid management, millions struggle to reach LDL-C goals. It's why ESPERION Therapeutics, Inc., the Lipid Management Company, developed NEXLIZET® (bempedoic acid and ezetimibe), the first oral nonstatin LDL-C lowering therapy with the dual mechanisms of bempedoic acid, the first adenosine triphosphate citrate lyase (ACL) inhibitor to reduce cholesterol biosynthesis in the liver, and ezetimibe, which reduces cholesterol absorption in the intestine. When added to maximally tolerated statin therapy, NEXLIZET delivered a significant mean 38% LDL-C reduction vs placebo, with incidence of most common adverse reactions generally comparable to placebo. See NEXLIZETHCP.com for product information, including side effects.